MedChina/MedRobot conducted an annual aggregation and market estimation of China’s orthopedic surgical robot sales in 2025. Using a unified research methodology, this report consolidates system deliveries and clinical usage across different commercial models, aiming to provide an industry-level, comparable, and discussion-oriented market reference.

Scope and Data Sources

This report covers orthopedic surgical robot sales in 2025 across China domestic market as well as overseas sales of Chinese brands.

The following categories are included:

• Public hospital procurement (including open tenders and selected non-public procurement channels)

• Private hospital procurement

• Technical service models (including pay-per-use, service-based, and quasi-leasing models)

• Overseas sales of Chinese brands

• OEM / co-branded system shipments

The following are excluded:

• Navigation-only systems or non-robotic products

• Systems with unclear product attributes or regulatory status

Data sources mainly include:

• MedRobot’s public hospital tender database

• Supplementary annual sales and delivery data provided by selected manufacturers

It should be noted that statistical standards may vary among companies. In addition, some international manufacturers, due to compliance requirements, can only provide public tender data as reference.

2025 Sales Volume (MedRobot Research Methodology)

Under the above methodology, MedChina/MedRobot estimates:

Total sales of orthopedic surgical robots in China in 2025 reached no less than 168 units, including domestic sales and overseas sales of Chinese brands. This figure should be regarded as a conservative estimate based on currently accessible information.

Manufacturer Sales Distribution (2025)

Total: ≥168 units

Note: All figures are compiled under MedRobot research methodology and are for industry research and trend observation only.

Market Structure: Concentration and Long Tail

The market shows clear concentration:

• Top 3 manufacturers account for over 80 units, around half of total sales.

• Top 5 manufacturers represent nearly two-thirds of the market.

• Top 8 manufacturers form the core commercial force.

From rank 10 onward, most companies sold only 1–5 units annually, reflecting a typical long-tail structure.

This indicates:

• Many companies remain in early or exploratory commercialization stages.

• Gaps in system maturity, clinical coverage, and commercial execution are being amplified by real market selection.

• The industry has entered a natural differentiation phase.

Structural Perspective Beyond Rankings

Although rankings are provided, orthopedic surgical robots include spine robots, joint replacement robots, and trauma robots, each with significantly different:

• Clinical scenarios

• Surgical complexity

• Surgeon dependence

• System architecture

• Hospital purchasing logic

Therefore, market evaluation should focus more on structural characteristics, including:

• Growth differences among procedure types

• Application distribution across hospital tiers

• Real clinical usage corresponding to different system positioning

In the long run, the orthopedic robot market is a multi-layered, structured, and downward-penetrating ecosystem, rather than a simple linear ranking system.

Domestic Manufacturers as the Main Market Force

Domestic manufacturers contribute the majority of market volume. Through advantages in clinical pathway adaptation, pricing systems, and localized services, Chinese companies have built increasing systemic competitiveness.

Orthopedic surgical robotics has become one of the fastest-commercializing segments within China’s high-end medical device industry.

Why the Market Appears “Highly Competitive”

The orthopedic surgical robot market is competitive not because it lacks value, but because its clinical value is being increasingly validated by hospitals.

Key inherent advantages include:

• Orthopedics is one of the largest surgical departments by volume.

• High procedural standardization suits robotic planning and execution.

• Strong dependence on precision and alignment.

• Capability-compensation value for lower-tier hospitals.

Meanwhile, barriers to adoption continue to decline:

• Device prices are gradually decreasing.

• Service-based and quasi-leasing models reduce upfront burden.

• Training and clinical support systems are improving.

• Interest from grassroots hospitals is rising.

As supply expands and product differentiation grows, the market is shifting from: “Do we need robots?” to “Which robot should we choose?” This is a long-term track with clear clinical value, real market space, and sustainable growth potential.

Conclusion

Overall, China’s orthopedic surgical robot market in 2025 demonstrates:

Emerging scale, clear tiers, domestic dominance, rising concentration, intense competition, and accelerating differentiation — all typical features of an early-stage commercial market.

At this stage, sales rankings reflect comprehensive system capability, market execution, and clinical adaptability, rather than final industry structure.

The long-term landscape will ultimately be determined by system stability, clinical value, and sustainable commercial capability.

MedChina, January 14, 2026